Federated Hermes, Inc. Crinetics Pharmaceuticals, Inc. Transaction History

Federated Hermes, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 08, 2024	BUY	$42.12 - $51.91 $517,696 - $638,025	12,291 Added 353.49%	15,768 $706,000
Q1 2024 May 14, 2024	BUY	$34.76 - $46.81 $120,234 - $161,915	3,459 Added 19216.67%	3,477 $162,000
Q4 2023 Jan 31, 2024	SELL	$25.62 - $37.07 $153 - $222	-6 Reduced 25.0%	18 $0
Q3 2023 Nov 13, 2023	BUY	$15.97 - $30.59 $383 - $734	24 New	24 $0
Q2 2022 Aug 15, 2022	SELL	$16.49 - $27.64 $420,198 - $704,322	-25,482 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$17.15 - $28.31 $11,078 - $18,288	646 Added 2.6%	25,482 $559,000
Q4 2021 Feb 14, 2022	BUY	$19.35 - $28.41 $480,576 - $705,590	24,836 New	24,836 $706,000
Q3 2020 Nov 12, 2020	SELL	$13.62 - $17.66 $871 - $1,130	-64 Closed	0 $0
Q2 2020 Aug 13, 2020	SELL	$13.04 - $23.23 $378 - $673	-29 Reduced 31.18%	64 $1,000
Q1 2020 May 13, 2020	BUY	$11.52 - $26.46 $1,071 - $2,460	93 New	93 $1,000

241

79.5M

23.3K

44.3K

Ticker CRNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,752,800
Market Cap $2.88B
Description
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.